SRC and prostate carcinoma: Since this novel mechanism of cellular regulation of COX2 activity by FYN should take place predominately in cancer cells and particularly in prostate cancer cells, which are characterized by enhanced expression of FYN in contrast to other members of the Src family [65], this will allow us to target COX2 in cancers cells without affecting COX2 function in normal cells.